CSL stock
Price history
+12.24% over the period1 year: from $180.44 (November 17, 2025) to $202.52 (November 16, 2026), +12.24%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $202.52 |
| October 30, 2026 | $200.73 |
| September 30, 2026 | $184.22 |
| August 31, 2026 | $171.57 |
| July 31, 2026 | $123.06 |
| June 30, 2026 | $114.74 |
| May 29, 2026 | $96.61 |
| April 30, 2026 | $124.37 |
| March 31, 2026 | $140.78 |
| February 27, 2026 | $146.76 |
| January 30, 2026 | $181.42 |
| December 31, 2025 | $172.65 |
| November 28, 2025 | $186.30 |
| November 17, 2025 | $180.44 |
At a glance
The company
Research, develops and distributes biopharmaceutical products and vaccines through CSL Behring, CSL Seqirus and CSL Vifor divisions
Latest results
Quarter to June 30, 2025 · EPS $2.04 (estimate $2.70)
TickerLandia's take on CSL
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.44% from the 52-week high
Analysts · 17 analysts
Average target$198.57−1.95% vs. price
Buy 9 · Hold 7 · Sell 1 · Buy
TickerLandia Fingerprint: CSL
Compared with similar companies: very strong momentum, very low growth, and very high dividend.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricelow37
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 6.12 31 Forward P/E 21.4 34 EV/EBITDA 21.3 46 Price/book 4.59 35 Profitabilitylow37
How much it earns on revenue and capital.
Metric Value Position in group Net margin −16.3% 22 Gross margin 51.1% 24 Operating margin 26.8% 63 ROE −15.8% 18 ROA 7.3% 58 Earnings stabilityvery high81
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.7% 99 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 62 Growthvery low17
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −404.00% 5 Revenue growth (year over year) +5.50% 25 Average revenue growth (3 years) +5.88% 20 Financial strengthlow26
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.67 16 Interest coverage 9.86 49 Current ratio 2.21 24 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.85 17 Dividendvery high81
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 2.0% 86 Consecutive dividend years at least 33 years 98 Payout ratio 45.1% 58 Market momentumvery strong89
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +49.28% 99 Relative strength (6 months) +95.19% 99 Distance from 200-day average +39.32% 98 1-year return +11.54% 58 Riskaverage43
How much the price swings.
Metric Value Position in group Beta (1 year) 0.67 46 Volatility (60 days) 19.8% 7 Maximum drawdown (12 months) 50.5% 77
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
CSL is cheaper than similar companies
CSL's Forward P/E: 21.4, −30% against the median of a group of 11 similar companies (30.4).
Compared with 11 similar companies
| Metric | CSL | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 21.4 | Low | |
| Operating margin | 26.8% | Middle | |
| ROE | -15.8% | Low | |
| Debt/equity | 0.67 | High | |
| Price/book | 4.59 | Middle |
Grey band: the middle half of the group; tick: the median; dot: CSL. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$7.47B
Latest quarter · Q2 2026
Net income
-$2.98B
Latest quarter · Q2 2026
Quarterly net margin
-39.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $96.75B
- EPS
- -$7.90
- Volume
- 156.42K
- Daily trading
- €118.28M
- Dividend yield
- 2.00%
- Last ex-dividend on September 9, 2026
How CSL is changing
All resultsRevenue grew 8.9% a year on average over the last 5 years
Operating margin rose from 25.7% to 26.8%
Shares outstanding up 5.7% in 5 years
Returns
CSL returns with dividends
$1,000 invested in CSL 5 years ago, on November 16, 2021, would be worth $716 today with dividends reinvested: −28.40% in total, −6.46% per year. On price alone it would be $659 (−34.12%).
| Period | CSL | S&P/ASX 200 | $1,000 becomes |
|---|---|---|---|
| 1 month | +5.37% | +3.40% | $1,054 |
| 6 months | +106.74% | +5.23% | $2,067 |
| Year to date | +17.30% | +4.22% | $1,173 |
| 1 year | +15.13% | +5.16% | $1,151 |
| 3 years | −16.82% | +28.67% | $832 |
| 5 years | −28.40% | +22.40% | $716 |
| 10 years | +135.44% | +70.47% | $2,354 |
Over the last 6 months it has done better than 98% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P/ASX 200: price only. Calculate your investment
The chart in detail
CSL: technical analysis
CSL is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 40.6% below its all-time closing high ($341.00, February 19, 2020).
- Trend
- Upward
- RSI (14 sessions)
- 67
- Between 30 and 70
- vs 200-session average
- +38.95%
Active signals
The price is moving in an unusually narrow range compared with the last year.
Support and resistance
Price areas where CSL has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$202.52
- Support$185.61−8.35%4 touches, last on October 1, 2026
- Support$176.00−13.10%5 touches, last on October 2, 2026
- Support$144.91−28.45%2 touches, last on April 8, 2026
Volatility and risk
Over the last year it has moved less than the S&P/ASX 200.
- Beta (1 year) vs S&P/ASX 200
- 0.68
- Volatility (60 sessions, annualised)
- 19.8%
- Largest fall in the last year
- −50.49%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
CSL: seasonality
Average monthly price change over 33 years
Over the last 33 years, the strongest month for CSL has been August: +4.54% on average, positive in 22 years out of 33. The weakest has been May: −0.28% on average, positive in 19 years out of 32. November, the current month, has been positive in 22 years out of 32 (+3.29% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.89% | +2.07% | 20 of 32 |
| February | +2.01% | +2.19% | 17 of 32 |
| March | +0.24% | +0.12% | 16 of 32 |
| April | +1.34% | +2.30% | 22 of 32 |
| May | −0.28% | +1.67% | 19 of 32 |
| June | +2.53% | +0.87% | 18 of 33 |
| July | +2.30% | +1.88% | 21 of 33 |
| August | +4.54% | +2.91% | 22 of 33 |
| September | +0.33% | +0.27% | 17 of 33 |
| October | +0.78% | +0.20% | 17 of 33 |
| November | +3.29% | +3.44% | 22 of 32 |
| December | +2.77% | +2.80% | 21 of 32 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
CSL and its competitors
Known to many through its CSL Behring plasma products, CSL Seqirus influenza vaccines and CSL Vifor iron deficiency and nephrology treatments, the company researches, develops, manufactures and distributes biopharmaceutical products and vaccines. Its therapeutic areas include immunoglobulins, immunology, haematology, cardiovascular and renal conditions, and vaccines, with gene therapies and recombinant products also part of its portfolio. Sales reach customers in Australia, the United States, Germany, the United Kingdom, Switzerland, China and Hong Kong, as well as internationally.
- Headquarters
- Melbourne, Australia
- Employees
- 29,000
- Founded
- 1916
- Chief executive
- Gordon Naylor
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| CSLCSL | $65.65B | 26.8% | — | +106.74% |
| Samsung Biologics207940 | $49.13B | 45.5% | 33.4 | +0.28% |
| Celltrion068270 | $36.68B | 31.6% | 26.4 | +19.29% |
| WuXi Biologics (Cayman)2269 | $24.52B | 32.4% | 35.1 | +38.78% |
| Innovent Biologics1801 | $18.84B | 7.4% | 111.5 | +2.32% |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | $13.65B | -0.2% | — | +0.78% |
Same industry or related industries, similar size. Compare CSL with its competitors · Full profile
